ADCC

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, April 9, 2024
HER2, CD8, Phosphorylation, Survival, Cholangiocarcinoma, Immunotherapy, RECIST, Oncology, MAST, Patient, City, Degranulation, ASX, ADCC, Cancer, Hope, Overalls, Pembrolizumab, PRS, AACR, SPECT, Vaccination, Melanoma, Recurrence, PD-L1, IMU, Medical imaging

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.

Key Points: 
  • Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.
  • SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIRE) -- Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.
  • HER-Vaxx induced HER2-specific antibodies able to mediate antibody-dependent cell cytotoxicity (ADCC) and inhibit intracellular HER2 phosphorylation and correlated with tumour reduction.
  • The HER-Vaxx induced HER2-specific antibodies demonstrate a similar mechanism of action to HERCEPTINâ validating B cell immunotherapy as an alternative anti-cancer agent to monoclonal antibodies.

Hong Kong Ferry Group Co-organised Anti-Deception Ferry “Ping On” Launching Ceremony and Harbour Cruise Tour

Retrieved on: 
Friday, February 9, 2024
Education, Ping On, Commissioner, Deception, Hong Kong Police Force, Operation, Commercial, Friends, Seemabaddha, Holding, Police, ADCC, PRW, Cryptocurrency

Every day the ferry travels during the daytime between Kwun Tong and North Point while in the evenings, it offers sightseeing services around Victoria Harbour.

Key Points: 
  • Every day the ferry travels during the daytime between Kwun Tong and North Point while in the evenings, it offers sightseeing services around Victoria Harbour.
  • After the launching ceremony, the ferry immediately embarked on a tour around Victoria Harbour.
  • He urged citizens to download the " Scameter " app to obtain relevant information and stay informed about scam prevention.
  • Mr. Gabriel Lee, Group Executive Director and General Manager of Hong Kong Ferry Group, said, “Over the past decades, the Group has successfully transformed from a ferry and shipyard focused business into an integrated conglomerate.

Agilent Wins Two Scientists’ Choice Awards for Drug Discovery and Development Products

Retrieved on: 
Thursday, February 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Media, Communications, ADCC, Tumor microenvironment, Agilent Technologies, CPE, RTCA, Drug discovery, Exhibition, Advantage Business Media, Conference, BioTek

Agilent Technologies Inc. (NYSE: A) announced today that it has received two prestigious awards from SelectScience: Best New Drug Discovery & Development Product of 2023 and Drug Discovery & Development Webinar of the Year.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) announced today that it has received two prestigious awards from SelectScience: Best New Drug Discovery & Development Product of 2023 and Drug Discovery & Development Webinar of the Year.
  • These accolades highlight Agilent’s commitment to innovation and excellence in drug discovery and development.
  • The Agilent xCELLigence RTCA HT-BioTek BioSpa 8 – Screening Model was voted Best New Drug Discovery & Development Product of 2023.
  • The Drug Discovery & Development Webinar of the Year was co-produced between Agilent and Dr. Agapitos Patakas, Chief Scientific Officer, Antibody Analytics.

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Retrieved on: 
Thursday, January 25, 2024
WuXi Biologics, Patient, Fucose, ADCC, Vaccine

SHANGHAI, Jan. 24, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has launched WuXiaADCC PLUSTM, a superior-performing and high-yielding mammalian cell line platform for the development and manufacturing of afucosylated antibodies to elicit an enhanced ADCC response (Figure 1).

Key Points: 
  • SHANGHAI, Jan. 24, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has launched WuXiaADCC PLUSTM, a superior-performing and high-yielding mammalian cell line platform for the development and manufacturing of afucosylated antibodies to elicit an enhanced ADCC response (Figure 1).
  • The development of novel cancer therapies entails designing and engineering antibodies with increased ability to heighten the ADCC response, which is known to improve therapeutic efficacy and patient outcomes.
  • To meet growing global demand for the production of afucosylated antibodies, the WuXiaADCC PLUSTM cell line was derived from the WuXi Biologics' highly-vetted WuXiaTM cell line.
  • The WuXiaADCC PLUSTM cell line is compatible with the WuXiaTM platform process, which enables the stable production of the afucosylated antibodies at various scales for clinical and commercial manufacturing.

Comprehensive Review Highlights Importance of Leukine® in Combination with Anti-GD2 Immunotherapy for Treatment of High-Risk Pediatric Neuroblastoma

Retrieved on: 
Wednesday, January 17, 2024
Lazarus, Neutrophil, Macrophage, Therapy, Canadian International Council, Hook effect, Hematology, G-CSF, Sant Joan, Safety, Hospital, MHC, FDA, PTX, INT, GM-CSF, ADCC, B cell, Vaccine

LEXINGTON, Mass., Jan. 17, 2024 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced today the publication of a comprehensive review by Mora et al.

Key Points: 
  • LEXINGTON, Mass., Jan. 17, 2024 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced today the publication of a comprehensive review by Mora et al.
  • It also describes why the authors believe it is suboptimal to replace with Leukine with G-CSF in this regimen for mechanistic reasons.
  • Leukine has been studied extensively in combination with dinutuximab and naxitamab leading to improved patient outcomes.
  • As a result, all clinical trials supporting the FDA-approval of dinutuximab and naxitamab included Leukine and both products are labeled for use in combination with GM-CSF.

Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

Retrieved on: 
Tuesday, January 16, 2024
ATLAS, Patient, UAS, Safety, Lirentelimab, PIN, Eosinophil, Webcast, Atopic dermatitis, ADCC, Pharmaceutical industry

SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced topline data from its phase 2 clinical trial in patients with atopic dermatitis (ATLAS) and from its Phase 2b clinical trial in patients with chronic spontaneous urticaria (MAVERICK).

Key Points: 
  • In the ATLAS trial, lirentelimab-treated patients’ blood eosinophils decreased by 96% versus placebo-treated patients’ blood eosinophils which decreased by 15%.
  • In the MAVERICK trial, lirentelimab-treated patients’ blood eosinophils decreased by 95% versus placebo-treated patients’ blood eosinophils which increased by 9%.
  • Across both trials safety was similar to previous clinical trials of lirentelimab.
  • In the ATLAS trial, 18.5% of lirentelimab treated patients experienced IRRs versus 6.2% of placebo treated patients.

MONJUVI (tafasitamab-cxix) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Pharmaceutical, Health, Oncology, Health Canada, Research, Immune system, Lenalidomide, European Commission, MHRA, Clinical trial, Civil service commission, Tafasitamab, CD19, ADCC, SWOT, EU4, ADCP, Fine chemical, Vaccine, Pharmaceutical industry, Risk management, DLBCL

This "MONJUVI Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MONJUVI for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.

Key Points: 
  • This "MONJUVI Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MONJUVI for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • Further, it also consists of future market assessments inclusive of the MONJUVI market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.
  • What are the other emerging products available and how are these giving competition to MONJUVI for DLBCL?

Artiva Biotherapeutics Receives Immunology Innovation of the Year in the 2023 BioTech Breakthrough Awards Program

Retrieved on: 
Wednesday, November 8, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, SLE, Lupus nephritis, IND, CD16, CD20, Northwest Biotherapeutics, GVHD, Neurotoxicity, ADCC, NK, Cancer, Cytokine release syndrome, Rituximab, Immunotherapy, Autoimmune disease, Safety, Hospital, Patient, Lupus, Vaccine

This year’s program attracted more than 1,500 nominations from over 12 different countries throughout the world.

Key Points: 
  • This year’s program attracted more than 1,500 nominations from over 12 different countries throughout the world.
  • Seminal clinical data with autologous CAR-T cells suggests that deep B cell depletion can induce complete and long-lasting responses in patients with lupus nephritis.
  • “The use of autologous CAR-T cells requires apheresis, likely hospitalization, and the potential for serious side effects.
  • “We’re pleased to recognize Artiva with ‘Immunology Innovation of the Year’ for their pipeline of off-the-shelf, allogeneic NK cell therapies that have the potential to be safe and immediately accessible to patients in need,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards.

Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Retrieved on: 
Friday, November 3, 2023
IZI, Society for Immunotherapy of Cancer, Affimer, Engineering, Poster, SITC, Immunotherapy, ADCC, NK, Cell therapy, Society, Cancer, Patient, Fraunhofer Society, Fertilizer, Vaccine

“This is the first direct comparison of NK cells redirected by Affimed’s ICE® with CAR-NK cells,” said Dr. Arndt Schottelius, Chief Scientific Officer at Affimed.

Key Points: 
  • “This is the first direct comparison of NK cells redirected by Affimed’s ICE® with CAR-NK cells,” said Dr. Arndt Schottelius, Chief Scientific Officer at Affimed.
  • The combination of allogeneic NK cells with ICE® molecules represents the most straightforward way to generate potent and targeted NK cells.
  • The combination of the ICE® molecule with NK cells or CAR-NK cells enhanced antibody-dependent cellular cytotoxicity (ADCC) against tumor cells and mediated elevated levels of degranulation when compared to NK cells or CAR-NK cells alone.
  • In conclusion, the combination of NK cells with ICE® represents a straight-forward way to potently target and activate NK cells.

Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120

Retrieved on: 
Monday, October 23, 2023
Medulloblastoma, Bone marrow, Plasma, AUC, Acute myeloid leukemia, Cmax, ESMO, Erythropoiesis, Principal investigator, Aes, PD, Congress, MD, Adenoid cystic carcinoma, CEST, Ruxolitinib, Cell, Data, Syndrome, All-comers track meet, Phase, SD, Risk, Webcast, Pancreatic cancer, Venetoclax, NPM1, WSE, ADCC, Safety, European Society for Medical Oncology, Patient, AML, Sarcoma, Pharmaceutical industry, Medical imaging, Dietary supplement

The total budget for the Phase II clinical development of RVU120 aligns with the estimates initially announced in the Ryvu Development Plans for 2022-2024.

Key Points: 
  • The total budget for the Phase II clinical development of RVU120 aligns with the estimates initially announced in the Ryvu Development Plans for 2022-2024.
  • The presented RVU120 development plan aligns with the budget outlined in Ryvu Development Plans for 2022-2024 and targets multi-billion-dollar market potential.
  • At the ESMO Congress 2023, Ryvu announced updated clinical Phase I data from Phase I/II study of RVU120 in relapsed/refractory metastatic advanced solid tumors.
  • Ryvu will host a webinar today (Monday, October 23) at 9:00 am CEST to discuss further RVU120 development plans.